The latest health news highlights Britain's stance on the bioethanol industry, Berkshire Hathaway's investment moves, the FTC's probe into Hims & Hers, Scorpion Capital's position on Soleno ...

Investors with substantial losses have the opportunity (until August 25, 2025) to move the court for appointment as Lead Plaintiff. Shareholder rights firm Hagens Berman is investigating the legal ...

Recent health-related developments include Britain's decisions on the bioethanol industry, Berkshire Hathaway's new stake in ...

Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face ...

US stocks opened mixed Friday as strong retail sales data offset hotter wholesale inflation, with UnitedHealth surging on ...

The disclosure in a filing Thursday gave a much-needed boost to the beleaguered health insurance giant, which saw shares jump as much as 9.6% in post-market trading. In other news: Nike co-founder ...

Hims & Hers first told investors about a regulatory review in July 2024, but Bloomberg's report adds new color on what ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

After Bloomberg reported, citing people familiar with the probe, that the Federal Trade Commission has been investigating ...

Investing.com -- Hims & Hers Health (NYSE:HIMS) stock dropped 2.6% on Friday following reports that the Federal Trade Commission has been investigating the telehealth company's business practices for ...

Telehealth company Hims & Hers Health’s (HIMS) business practices have been under investigation by the U.S. Federal Trade Commission (FTC) for over a year, Bloomberg reported. Following the news, HIMS ...